Anna Protopapas - 15 Jul 2026 Form 4 Insider Report for Nuvalent, Inc. (NUVL)

Reporting relationship: Director
Issuer ticker: NUVL
Reported as of: 15 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jul 2026, 18:36:35 UTC
Prior SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Nathan McConarty, Attorney-in-Fact

Key filing fact

Anna Protopapas filed Form 4 for Nuvalent, Inc. (NUVL) on 15 Jul 2026.

Key facts

This page summarizes Anna Protopapas's Form 4 filing for Nuvalent, Inc. (NUVL).
6 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 15 Jul 2026, 18:36.

Change

Previous filing in this sequence was filed on 18 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001347582 Primary reporting owner

Protopapas Anna

Relationship: Director
Address: C/O NUVALENT, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Signature: /s/ Nathan McConarty, Attorney-in-Fact
Signature date: 15 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NUVL transaction

Class A Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -5,146
Change %: -100%
Price: $124.00^*
Shares after: 0
Date: 15 Jul 2026
Ownership: Direct
Footnotes: F1, F2

NUVL transaction

Class A Common Stock - Restricted Stock Units

Disposed to Issuer

Transaction value
Shares: -3,444
Change %: -100%
Price
Shares after: 0
Date: 15 Jul 2026
Ownership: Direct
Footnotes: F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NUVL transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -40,000
Change %: -100%
Price
Shares after: 0
Date: 15 Jul 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 40,000
Exercise price: $14.08
Footnotes: F5

NUVL transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -15,000
Change %: -100%
Price
Shares after: 0
Date: 15 Jul 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 15,000
Exercise price: $9.36
Footnotes: F5

NUVL transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -3,789
Change %: -100%
Price
Shares after: 0
Date: 15 Jul 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 3,789
Exercise price: $80.03
Footnotes: F5

NUVL transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -4,147
Change %: -100%
Price
Shares after: 0
Date: 15 Jul 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 4,147
Exercise price: $75.53
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Anna Protopapas is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 5 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger, dated June 9, 2026 (the "Merger Agreement"), by and among (i) Nuvalent, Inc., a Delaware corporation (the "Company"), (ii) GlaxoSmithKline LLC, a Delaware limited liability company ("Parent"), (iii) Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and (iv) solely for purposes of Section 9.14 therein, GSK plc, a public limited company organized under the laws of England and Wales ("Ultimate Parent"), Purchaser completed a tender offer (the "Offer") to purchase all outstanding shares of Class A Common Stock of the Company and Class B Common Stock of the Company. The shares of Class A Common Stock of the Company and Class B Common Stock of the Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $124.00 per share, net to the seller in cash, without interest (the "Offer Price"), subject to applicable withholding tax.

Footnote F2

(Continued from footnote 1) After completion of the Offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

Footnote F3

Each restricted stock unit represents a contingent right to receive one share of Class A Common Stock of the Company.

Footnote F4

Pursuant to the Merger Agreement, each restricted stock unit that was subject solely to time-based vesting (a "Company RSU") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company RSU immediately prior to the effective time of the Merger and (y) the Offer Price.

Footnote F5

Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option.